Latest Morpholines Stories
Data from Once-Weekly CHAMPION Phase 1/2 Study Presented at ASCO THOUSAND OAKS, Calif., May 31, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the initiation of the ARROW
Janssen Expands EXPLORER Cardiovascular Research Program to Include New, Multi-Trial, Prospective Research Program Aimed at Generating New Evidence in Treating and Preventing Cancer-Associated Blood
THOUSAND OAKS, Calif., May 27, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple Kyprolis(®) (carfilzomib) for Injection, BLINCYTO(®) (blinatumomab),
Results Add to Findings from Ongoing Five-Year Post-Marketing Safety Program of XARELTO® Use in Clinical Practice NATIONAL HARBOR, Md., May 15, 2015 /PRNewswire/ -- New data from an ongoing
NEW YORK, April 21, 2015 /PRNewswire/ -- The New York City law firm of Rheingold, Valet, Rheingold, McCartney & Giuffra LLP this week commenced two wrongful death lawsuits, each involving
GENEVA, April 17, 2015 /PRNewswire/ -- ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative
Application Designed to Support Conversion of Accelerated to Full FDA Approval THOUSAND OAKS, Calif., March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
The San Diego based law firm with its national network of experienced lawyers comments on the FDA's Adverse Reaction changes to the anticoagulant's labeling, as well as the development
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Feb.
-- Phase 1 Studies Confirm Superior Safety Profile of MRX-I Over Zyvox® -- HAYWARD, Calif. and SHANGHAI, Feb.
- The parings of haberdine; also, any kind of fragments.